ASP-1012 is under clinical development by KaliVir Immunotherapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASP-1012’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASP-1012 overview

ASP-1012 (VET-2L2) is under development for the treatment of metastatic solid tumors, gastric cancer, gastroesophageal junction carcinoma, metastatic melanoma and metastatic ovarian cancer resistant to PD-1/PD-L1 antibody. It is administered through intravenous route. The therapeutic candidate comprises of genetically modified Vaccinia virus and acts by targeting leptin and interleukin-2 (IL-2). It is being developed based on vaccinia enhanced template (VET) platform.

KaliVir Immunotherapeutics overview

Kalivir Immunotherapeutics (Kalivir) is a biotechnology company that develops oncolytic viral immunotherapies for cancer. It is investigating VET2-L2, a leptin based drug and VET-S3, a STAT3 (signal transducer and activator of transcription 3) inhibitor to treat metastatic solid tumors resistant to PD1/L1 antibody by destroying cancer cells and activating anti-cancer immunity. The company is also evaluating VET-X1 and VET-X drugs against solid tumors. Kalivir utilizes its proprietary vaccinia enhanced template (VET) platform technology to generate potent novel oncolytic vaccinia viruses with modifications, maximize viral replication and improve intravenous delivery and spread. Kalivir is headquartered in Pittsburgh, Pennsylvania, the US.

For a complete picture of ASP-1012’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.